open access

Vol 15, No 2 (2019)
Review paper
Published online: 2019-02-27
Get Citation

Neratinib in adjuvant treatment of patients with HER2-positive breast cancer — less is more?

Ewa Cedrych, Ida Cedrych
DOI: 10.5603/OCP.2019.0014
·
Oncol Clin Pract 2019;15(2):111-114.

open access

Vol 15, No 2 (2019)
REVIEW ARTICLES
Published online: 2019-02-27

Abstract

Neratinib is a new small molecule aimed at HER2 receptor. It has recently been approved in the United States of America and Europe for adjuvant treatment of patients with early, HER2-positive breast cancer, who underwent surgical resection followed by at least one year of adjuvant trastuzumab treatment. Despite initial enthusiasm, several factors limit the implementation of neratinib in clinical practice. These include: modest reduction of recurrence rate; limited data regarding the effect on overall survival; and a significant rate of adverse events. Thus, neratinib should be considered mainly in patients with high-risk HER2-positive breast cancer, because its clinical benefit might outweigh the side effects in this population. In the following article, we discuss the controversies regarding the pivotal phase III trial that eventually led to neratinib approval.

Abstract

Neratinib is a new small molecule aimed at HER2 receptor. It has recently been approved in the United States of America and Europe for adjuvant treatment of patients with early, HER2-positive breast cancer, who underwent surgical resection followed by at least one year of adjuvant trastuzumab treatment. Despite initial enthusiasm, several factors limit the implementation of neratinib in clinical practice. These include: modest reduction of recurrence rate; limited data regarding the effect on overall survival; and a significant rate of adverse events. Thus, neratinib should be considered mainly in patients with high-risk HER2-positive breast cancer, because its clinical benefit might outweigh the side effects in this population. In the following article, we discuss the controversies regarding the pivotal phase III trial that eventually led to neratinib approval.
Get Citation

Keywords

neratinib; breast cancer; HER2

About this article
Title

Neratinib in adjuvant treatment of patients with HER2-positive breast cancer — less is more?

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 2 (2019)

Article type

Review paper

Pages

111-114

Published online

2019-02-27

DOI

10.5603/OCP.2019.0014

Bibliographic record

Oncol Clin Pract 2019;15(2):111-114.

Keywords

neratinib
breast cancer
HER2

Authors

Ewa Cedrych
Ida Cedrych

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl